Clovis Oncology (CLVS) Holdings Increased by Candriam Luxembourg S.C.A.

Candriam Luxembourg S.C.A. boosted its position in Clovis Oncology (NASDAQ:CLVS) by 166.7% during the 1st quarter, HoldingsChannel reports. The firm owned 781,623 shares of the biopharmaceutical company’s stock after purchasing an additional 488,523 shares during the quarter. Candriam Luxembourg S.C.A.’s holdings in Clovis Oncology were worth $19,401,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of CLVS. Great West Life Assurance Co. Can lifted its stake in Clovis Oncology by 54.8% in the 4th quarter. Great West Life Assurance Co. Can now owns 7,034 shares of the biopharmaceutical company’s stock worth $122,000 after purchasing an additional 2,489 shares in the last quarter. Two Sigma Securities LLC purchased a new stake in shares of Clovis Oncology during the 4th quarter valued at $212,000. Virtu Financial LLC purchased a new stake in shares of Clovis Oncology during the 1st quarter valued at $215,000. Gabelli Funds LLC raised its position in shares of Clovis Oncology by 115.9% during the 4th quarter. Gabelli Funds LLC now owns 14,900 shares of the biopharmaceutical company’s stock valued at $268,000 after buying an additional 8,000 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY raised its position in shares of Clovis Oncology by 356.7% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 15,513 shares of the biopharmaceutical company’s stock valued at $279,000 after buying an additional 12,116 shares in the last quarter.

Several analysts have recently weighed in on CLVS shares. HC Wainwright started coverage on shares of Clovis Oncology in a research report on Wednesday, February 13th. They set a “buy” rating and a $40.00 price objective on the stock. Zacks Investment Research cut shares of Clovis Oncology from a “hold” rating to a “sell” rating in a research report on Tuesday, February 19th. JPMorgan Chase & Co. restated a “hold” rating and set a $27.00 price objective on shares of Clovis Oncology in a research report on Wednesday, February 27th. BidaskClub upgraded shares of Clovis Oncology from a “sell” rating to a “hold” rating in a research report on Friday, March 1st. Finally, Piper Jaffray Companies raised their price objective on shares of Clovis Oncology to $23.00 and gave the company a “neutral” rating in a research report on Wednesday, February 27th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and eight have assigned a buy rating to the company. Clovis Oncology has an average rating of “Hold” and a consensus price target of $34.63.

In related news, Director James C. Blair sold 17,056 shares of Clovis Oncology stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $27.79, for a total value of $473,986.24. Following the transaction, the director now owns 13,439 shares in the company, valued at approximately $373,469.81. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Lindsey Rolfe sold 1,729 shares of Clovis Oncology stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $26.13, for a total transaction of $45,178.77. Following the completion of the transaction, the insider now owns 20,953 shares in the company, valued at approximately $547,501.89. The disclosure for this sale can be found here. In the last quarter, insiders sold 20,782 shares of company stock worth $576,755. 10.20% of the stock is owned by corporate insiders.

Clovis Oncology stock opened at $19.10 on Tuesday. The company has a current ratio of 4.55, a quick ratio of 4.34 and a debt-to-equity ratio of 3.93. Clovis Oncology has a fifty-two week low of $11.50 and a fifty-two week high of $53.90.

Clovis Oncology (NASDAQ:CLVS) last issued its earnings results on Tuesday, February 26th. The biopharmaceutical company reported ($1.88) EPS for the quarter, missing analysts’ consensus estimates of ($1.68) by ($0.20). The business had revenue of $30.40 million during the quarter, compared to analysts’ expectations of $30.46 million. Clovis Oncology had a negative return on equity of 147.39% and a negative net margin of 385.80%. Clovis Oncology’s revenue for the quarter was up 78.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.04) EPS. As a group, equities analysts expect that Clovis Oncology will post -6.99 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This piece was first reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://www.thelincolnianonline.com/2019/05/07/clovis-oncology-clvs-holdings-increased-by-candriam-luxembourg-s-c-a.html.

Clovis Oncology Profile

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

See Also: Net Income

Want to see what other hedge funds are holding CLVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clovis Oncology (NASDAQ:CLVS).

Institutional Ownership by Quarter for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.